CClinicalTrials.gg
Sign In
Not yet recruitingNCT05998811Updated Aug 21, 2023

Insights Into Participating in Studies for Uterine Cancer

An observational study in Uterine Cancer, sponsored by Power Life Sciences Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by Power Life Sciences Inc. · Observational

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Clinical study participation has historically been heavily biased toward specific demographics.

Several people will be invited to enroll in this trial so that it may collect a variety of data about uterine cancer clinical study experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.

People with uterine cancer who are invited to take part in medical study will benefit from the analysis of the data.

02

Conditions studied

  • Uterine Cancer

Browse trials for

Keywords

  • Uterine Cancer
03

In context

Uterine Neoplasms

255 studies on the registry are indexed under Uterine Neoplasms; 64 are open to participants now.

This study's planned enrollment of 500 is above the median of 220 across 64 observational studies indexed under Uterine Neoplasms.

Browse Uterine Neoplasms studies →

Lead sponsor

Power Life Sciences Inc. is the lead sponsor of 108 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Uterine cancer patients who are actively considering enrolling in a clinical trial for the said condition, but have not yet completed enrollment and randomization phases.

Inclusion criteria

  • Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
  • Diagnosis of uterine cancer
  • No prior treatment for uterine cancer

Exclusion criteria

Exclusion Criteria:

  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Enrolled in another research study
  • Inability to provide written informed consent
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of patients who decide to enroll in a uterine cancer clinical research

    Time frame: 3 months

  2. Rate of patients who remain in a uterine cancer clinical trial to trial completion

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Filippova OT, Leitao MM. The current clinical approach to newly diagnosed uterine cancer. Expert Rev Anticancer Ther. 2020 Jul;20(7):581-590. doi: 10.1080/14737140.2020.1782750. Epub 2020 Jun 22. PubMed 32531179 ↗
  • Wang Z, Guo E, Yang B, Xiao R, Lu F, You L, Chen G. Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer. Gynecol Oncol. 2021 Nov;163(2):358-363. doi: 10.1016/j.ygyno.2021.08.029. Epub 2021 Sep 8. PubMed 34507827 ↗
  • Torres D, Myers JA, Eshraghi LW, Riley EC, Soliman PT, Milam MR. Risk factors for the development of uterine cancer in breast cancer survivors: an army of women study. Ann Surg Oncol. 2015;22(6):1974-9. doi: 10.1245/s10434-014-4193-5. Epub 2014 Nov 1. PubMed 25361886 ↗

Study documents

  • Informed consent form · Aug 11, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05998811
Lead sponsor
Power Life Sciences Inc.
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Sep 2024 (estimated)
Primary completion
Sep 2025 (estimated)
Completion
Sep 2026 (estimated)
Last update
Aug 21, 2023

Study contacts

Michael B Gill
Contact
bask@withpower.com
4159004227
Michael B Gill
study director · Power Life Sciences Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Uterine Neoplasms→

Other studies from this sponsor

Power Life Sciences Inc.

Start the discussion